Kharfan-Dabaja, M. A., Komrokji, R. S., Zhang, Q., Kumar, A., Tsalatsanis, A., Perkins, J., . . . Padron, E. (2017). TP53 and IDH2 somatic mutations are associated with inferior overall survival following allogeneic hematopoietic cell transplantation for myelodysplastic syndrome. Clin Lymphoma Myeloma Leuk.
Styl ChicagoKharfan-Dabaja, Mohamed A., et al. "TP53 and IDH2 Somatic Mutations Are Associated With Inferior Overall Survival Following Allogeneic Hematopoietic Cell Transplantation for Myelodysplastic Syndrome." Clin Lymphoma Myeloma Leuk 2017.
Citace podle MLAKharfan-Dabaja, Mohamed A., et al. "TP53 and IDH2 Somatic Mutations Are Associated With Inferior Overall Survival Following Allogeneic Hematopoietic Cell Transplantation for Myelodysplastic Syndrome." Clin Lymphoma Myeloma Leuk 2017.